换一批
换一批Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.
作者：
主题词
成年人(Adult);慢性病(Chronic Disease);皮肤科用药(Dermatologic Agents);双盲法(Double-Blind Method);用药计划表(Drug Administration Schedule);女(雌)性(Female);人类(Humans);注射, 皮下(Injections, Subcutaneous);白细胞介素17(Interleukin-17);男(雄)性(Male);中年人(Middle Aged);银屑病(Psoriasis);疾病严重程度指数(Severity of Illness Index);治疗结果(Treatment Outcome)
DOI
10.1016/j.jaad.2018.03.037
PMID
29609013
发布时间
2019-12-10
- 浏览3
Journal of the American Academy of Dermatology
277-286.e10页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
